We previously reported that tacrolimus (TAC) trough blood concentrations for African
American (AA) kidney allograft recipients were lower than those observed in white patients …

Abstract Background: Tacrolimus (Tac) is an immunosuppressive drug used to prevent post-
transplant (PT) organ rejection. Continuous Tac monitoring is necessary to adjust the dose …

Desirable outcomes including rejection-and infection-free kidney transplantation are not
guaranteed despite current strategies for immunosuppression and using prophylactic …

Background: Calcineurin inhibition (CNI) is the mainstay of immunosuppressant therapy for
most solid organ transplant patients. High tacrolimus levels are related with acute …

To assess the prevalence of CYP 3A5 genomic variances and their impact on tacrolimus
(TAC) dosing requirements among kidney transplant recipients in eastern North Carolina …

Abstract The CYP3A5* 3 and CYP3A4* 1B alleles have been related with tacrolimus (Tac)
dose requirements. The rare CYP3A4* 22 variant has also been associated with a …

The efficacy and safety of tacrolimus‐and cyclosporine‐based immunosuppressive
regimens were compared in a prospectively defined subgroup of kidney transplant …

Background: The risk of long-term chronic allograft nephropathy and graft loss after kidney
transplantation is increased in patients with a high intrapatient variability of tacrolimus (Tac) …

Tacrolimus is a new macrolide immunosuppressant that was isolated from Streptomyces
tsukubaensis in 1984. In vitro, on a molecular basis, tacrolimus is 50 to 100 times more …

Background. The effect of potentially relevant genetic polymorphisms, CYP3A5 6986A> G
and ABCB1 3435C> T, on Tacrolimus pharmacokinetics and graft clinical outcome was …